Current status of adjuvant chemotherapy for stage IB non-small-cell lulng cancer: Implications for the new intergroup trial

Clinical Lung Cancer

Volumn 8, Issue 1, 2006, Pages 18-21

  Wakelee, Heather A ^a   Schiller, Joan H ^b   Gandara, David R ^c  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carboplatin; Cisplatin; Early stage; Postoperative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; UFT; VINCA ALKALOID; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CLINICAL TRIAL; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; SHORT SURVEY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 33748369295     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.028     Document Type: Review

References (19)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
2. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000; 343:1217-1222.
3. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26:173-182.
4. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461.
5. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360.
6. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-2597.
7. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with pacliraxel and carboplatin following resection in stage III non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004; 22:621s (Abstract #7019).
8. Douillard JY, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol 2005; 23(18 suppl):624s (Abstract #7013).
9. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update on Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006; 24(18 suppl):365s (Abstract #7007).
10. Pignon JP, Tribodet GV, Scagliotti G, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2006; 24(18 suppl):366s (Abstract #7008).
11. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713-1721.
12. Hamada C, Ohta M, Wada H, et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 2004; 22:617s (Abstract #7002).
13. Sandler A, Gray R, Brahmer JR, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005; 23(16 supl):2s (Abstract #LBA4).
14. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024.
15. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22:254-261.
16. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
17. Ardizzoni A, Tiseo M, Boni L, et al. CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):366s (Abstract #7011).
18. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:3852-3859.
19. Zojwalla NJ, Raftopoulos H, Gralla R. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients. J Clin Oncol 2004; 22:633s (Abstract #7068).